n the recent Lescol Intervention Prevention Study (LIPS), long-term therapy with fluvastatin decreased the incidence of cardiac events in patients who underwent percutaneous coronary intervention. 1 The present study analyzed the results of LIPS to investigate (1) the effect of baseline renal function on occurrence of long-term adverse events, (2) whether therapy with fluvastatin decreased the expected hazardous effect of renal impairment, (3) the effect of fluvastatin on renal function during follow-up, and (4) the relation between changes in renal function over time and the occurrence of adverse events.
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METHODS

Study design and patient population:
The study design and primary results of LIPS have been described elsewhere. 1 Briefly, after a first successful percutaneous coronary intervention (residual stenosis Ͻ50%, absence of postprocedural in-hospital myocardial necrosis, repeat revascularization, or death), patients were randomized to receive fluvastatin therapy (Lescol, Novartis Pharma AG, Basel, Switzerland; 40 mg 2 times daily) or placebo for 3 to 4 years.
At enrollment, patients had to fulfill Ն1 of the following lipid profile criteria: (1) total cholesterol level of 135 to 270 mg/dl with a fasting triglyceride level Ͻ400 mg/dl, (2) total cholesterol level Ͻ212 mg/dl for patients whose lipids levels were measured 24 hours to 4 weeks after an episode of myocardial infarction, or (3) total cholesterol level Ͻ232 mg/dl for patients who had diabetes mellitus. Exclusion criteria included a baseline serum creatinine value Ͼ1.8 mg/dl. The study protocol was approved by the local ethics committees, and all patients gave informed written consent.
Lipoproteins and evaluation of renal function: Each patient was clinically evaluated Ն8 times after randomization. Blood lipid levels were measured at all visits, and serum creatinine was measured at baseline and at 52, 104, and 156 weeks. All biochemical analyses were performed at a central laboratory (Analytico Medinet, Breda, The Netherlands). Creatinine clearance was calculated according to the formula proposed by Cockcroft and Gault 2 : creatinine clearance (milliliter/minute) ϭ (140 Ϫ age) ϫ weight (kilograms) Ϭ 72 ϫ serum creatinine (milligrams/deciliter) (ϫ 0.85 for women). 2 Clinical end points: Outcomes were evaluated as a composite of atherosclerotically related adverse cardiac events, defined as the incidence of cardiac death (all deaths except those unequivocally related to a noncardiac cause), nonfatal myocardial infarction (new pathologic Q waves or a total plasma creatine kinase level Ͼ2 times the normal upper limit with the MB isoenzyme), and all reinterventions (surgical or percutaneous) not caused by coronary restenosis occurring after the index procedure. Atherosclerotically related adverse cardiac events were a predefined end point of LIPS, 1 based on the demonstrated benefit of fluvastatin after percutaneous intervention being unrelated to any effect of the drug on restenosis. 3 In addition, the incidence of target lesion revascularization was analyzed in the 2 renal function groups.
Statistical analysis: All analyses were carried out on an intent-to-treat basis. Continuous variables were expressed as mean Ϯ SD and were compared with Student's unpaired t test. Fisher's exact test was used for categorical variables, and Wilcoxon's scores were used for categorical variables with an ordinal scale. Discrete variables were expressed as counts and percentages and were compared in terms of relative risks and 95% confidence intervals (CIs). All statistical tests were 2-tailed. Event-free survival distribution was estimated according to the KaplanMeier method, and overall incidence of adverse events was tested with the log-rank test. Cox's proportional hazards models were used to assess decreased risk of adverse events.
For illustrative purposes, patients were assigned to 1 of 2 groups according to baseline value of creatinine clearance; abnormal creatinine clearance was defined as a value in the lowest quintile (Ͻ55.9 ml/min). This restrictive definition was applied in accordance with the LIPS study protocol, which excluded patients who had markedly impaired renal function. All testing to assess the effect of renal function on outcomes was performed using baseline creatinine clearance as a continuous numeric variable. Estimated risk ratios were calculated from the observed data, with mean clearance of the entire study population as a reference point for the placebo group (risk ratio 1). Creatinine clearance measurements were converted by logarithmic transformation to normalize distribution of the data.
All baseline clinical, angiographic, and procedural characteristics available in the study database were tested to evaluate their relation to the incidence of clinical adverse events. Variables presenting a univariate p value Ͻ0.1 were tested as candidates in a Values are mean Ϯ SD or numbers (percentages). *Includes patients who had silent ischemia † Categories are not mutually exclusive ACE ϭ angiotensin-converting enzyme; ASA ϭ aspirin; CAD ϭ coronary atherosclerotic disease; HDL ϭ high-density lipoprotein; LAD ϭ left anterior descending artery; LCx ϭ left circumflex artery; LDL ϭ low-density lipoprotein; MI ϭ myocardial infarction; RCA ϭ right coronary artery.
multivariate analysis, and a final model was constructed by stepwise selection of the most significant variables (the following variables were selected from univariate analyses: allocated treatment, creatinine clearance, stable/unstable angina, smoking status, high-density lipoprotein cholesterol levels, gender, hypertension, diabetes, previous stroke, previous myocardial infarction, cholesterol-lowering diet, height, body mass index, diastolic blood pressure, systolic blood pressure, multivessel disease, pathologic Q wave in lead aVL, number of stents implanted, and number of sites with Thrombolysis In Myocardial Infarction grade 3 flow). Lipid profiles and clearance-time profile were analyzed by analysis of covariance models that incorporated baseline values as covariates and added factors of treatment, number of visits, and renal function subgroup with all possible interaction terms. To evaluate the relation between occurrence of clinical events and behavior of renal function over time, separate analyses were performed to evaluate the clearancetime profile for patients who had adverse events during follow-up and those who did not.
RESULTS
Patient population: Between April 1996 and October 1998, 1,677 patients were enrolled in the LIPS. Complete data for creatinine clearance calculation were available for 1,558 patients (92.9%) and were included in the present study. Table 1 lists baseline characteristics of 1,248 patients who had normal renal function (creatinine clearance above the first quintile or Ն55.9 ml/min) and of 310 patients who had impaired renal function (creatinine clearance in the lowest quintile or Ͻ55.9 ml/min). Overall, patients who had renal impairment were more likely to be older, to be women, to be lighter and shorter, and to have more severe coronary artery disease and co-morbidities.
Four groups were considered for analysis: (1) patients who had normal renal function and received placebo (n ϭ 617), (2) patients who had normal renal function and received fluvastatin (n ϭ 631), (3) patients who had impaired renal function and received placebo (n ϭ 160), and (4) patients who had impaired renal function and received fluvastatin (n ϭ 150). Baseline characteristics did not differ between fluvastatin and placebo groups (pooled across renal function categories) except that patients who received fluvastatin were taller (170 Ϯ 8 vs 169 Ϯ 8 cm, p ϭ 0.02) and heavier (77 Ϯ 11 vs 76 Ϯ 11 kg, p Ͻ0.01) and showed a higher prevalence of diabetes (14% vs 10%, p Ͻ0.01).
Cardiovascular events: Patients were followed for a mean of 3.8 Ϯ 0.1 years. Table 2 lists incidences of coronary atherosclerotic events according to allocated treatment and presence of renal impairment. Overall, fluvastatin therapy significantly decreased the incidence of adverse events (hazard ratio 0.69, 95% CI 0.55 to 0.87, p ϭ 0.002; Table 3 ). Moreover, baseline creatinine clearance (logarithmic transformation) was inversely associated with an incidence of adverse events in the overall population pooled by treatment (hazard ratio 0.99, 95% CI 0.98 to 0.99, p ϭ 0.02; Table 3 ). However, when analyzed separately, baseline creatinine clearance was significantly associated with outcomes of patients who received placebo (hazard ratio 0.99, 95% CI 0.982 to 0.998, p ϭ 0.01), whereas no association was noted among patients who received fluvastatin (hazard ratio 1.0, 95% CI 0.99 to 1.0, p ϭ 0.63; Table 3 ). Figures 1 and 2 show Kaplan-Meier curves of patients who received fluvastatin or placebo grouped according to presence of renal impairment or normal renal function. Among patients who received placebo, curves of patients who had renal impairment versus those who did not began to diverge after approximately 1 year (p ϭ 0.009 by log-rank test; Figure 2) . Conversely, among patients who received fluvastatin, curves of adverse events of patients who had renal impairment versus those of patients who had normal renal function remained overlapped throughout follow-up (p ϭ 0.92 by logrank test; Figure 2 ). No differences were observed in the incidence of repeat revascularization due to restenosis between patients who had renal impairment and those who did not (4.4% vs 5.2%, respectively, p ϭ 0.7). Lipoprotein levels and renal function outcome: Baseline lipoprotein levels were similar in the 2 renal function groups, with the exception of high-density lipoprotein cholesterol levels (Table 1) . By 6 weeks, fluvastatin significantly decreased levels of low-density lipoprotein cholesterol compared with placebo in patients who had renal impairment (median change with fluvastatin Ϫ24%, 95% CI Ϫ28 to Ϫ20 vs ϩ13%, 95% CI ϩ9 to ϩ17, p Ͻ0.001) and those who had normal renal function (Ϫ28%, 95% CI Ϫ30 to Ϫ25% vs ϩ11%, 95% CI ϩ9 to ϩ13%, p Ͻ0.001). The decrease was similar in patients who had renal impairment and those who did not and was maintained throughout the study. At the end of the study, no significant differences in triglyceride levels were observed between treatment groups. Levels of high-density lipoprotein cholesterol increased by a median of 12%, regardless of treatment allocation or baseline renal function.
Renal function remained stable throughout follow-up and the predicted clearance-time profile was not influenced by fluvastatin therapy, regardless of baseline creatinine clearance (Figure 3) . No significant changes were observed in renal function between patients who had adverse events during follow-up and those who did not (Figure 3) .
Predictors of increased cardiovascular risk: Figure 4 shows estimated risk ratios according to baseline creatinine clearance calculated by Cox's proportional hazards model from the observed data (mean clearance of the entire study population was chosen as a reference point for the placebo group, risk ratio 1). A progressive increase in the risk of long-term complications is predicted with lower values of creatinine clearance. However, fluvastatin therapy caused a downward shift and flattening of the entire risk ratio curve. Interestingly, a risk ratio of 1 was associated with a baseline creatinine clearance of ϳ70 ml/min in the placebo group but with a rate of only 25 ml/min in the fluvastatin group. Multivariate Cox's proportional hazards analysis identified creatinine clearance as an independent predictor of atherosclerotically related adverse cardiac events (Table 4) . Other variables significantly associated with an incidence of adverse events included fluvastatin therapy, diabetes mellitus, multivessel disease, and number of stents implanted during a procedure (Table 4) .
DISCUSSION
The major finding of the present study is that low values of creatinine clearance at baseline significantly increases the incidence of coronary adverse atherosclerotic events after a first successful percutaneous coronary intervention and that this effect is virtually abolished by long-term therapy with fluvastatin. The benefit of fluvastatin in patients who have renal impairment could not be explained by a differential action on lipid levels or on renal function during follow-up. Moreover, no association was observed between the incidence of adverse events and changes in renal function during follow-up. In addition to procedures to alleviate symptoms and myocardial ischemia, secondary prevention of further adverse events constitutes a key paradigm in the long-term management of patients who have diagnosed coronary disease. Although the need for repeat intervention has been recognized as the major limitation of angioplasty, the newly introduced drugeluting stents have been shown to markedly decrease restenosis rates. 4 In this context, adoption of procedures aimed at modifying the natural course of atherosclerotic disease (i.e., non-restenosis-related complications) becomes the main focus of attention after percutaneous control. In the present study, fluvastatin was shown to significantly decrease the incidence of adverse events after angioplasty in patients who had renal dysfunction and those who did not.
Secondary prevention strategies constitute a range of methods to decrease the effect of known risk factors on outcomes of patients who have diagnosed coronary disease. Ideally, management of a particular risk factor should decrease the risk of patients who receive treatment to the level of subjects who do not have the condition. Mild renal impairment has been identified as an important predictor of adverse events in patients who have previous cardiovascular disease. [5] [6] [7] [8] [9] [10] [11] [12] Although diureticbased blood pressure control and long-term ramipril therapy have been reported to improve clinical outcomes, the hazardous effect of mild renal impairment was only partly decreased by these therapies. 11, 13 Pravastatin has recently been shown to decrease the incidence of events in patients who have renal dysfunction; in contrast to most reports, the presence of renal impairment did not influence late clinical outcomes in that study. 14 Moreover, the extent to which statins decreased the risk of future complications was not evaluated in relation to patients who had normal renal function. 14 In the present study, renal impairment significantly and independently impaired long-term clinical outcomes after coronary intervention. Notably, fluvastatin therapy equalized outcomes of patients who had renal impairment and those who had normal renal function, thus virtually abolishing the hazardous effect of renal dysfunction.
In contrast to previous studies, 15 no effect of fluvastatin therapy on renal function was observed during the 4-year follow-up. These results suggest that the benefit of fluvastatin was not mediated by a direct effect to stabilize or improve creatinine clearance. Moreover, occurrence of adverse events was not related to changes in renal function. In addition, the effect of fluvastatin in patients who had renal dysfunction could not be explained by a more pronounced lipid decrease in this group. These results suggest that the benefit of statins in patients who have renal impairment may be associated with mechanisms that are not related to a direct effect on kidney physiology and are independent of their lipid-lowering effects. Although not assessed in the present study, statins have been widely reported to exert beneficial effects on a variety of pathophysiologic atherogenic mechanisms that are altered in patients who have renal impairment. 16 -24 Study limitations: The present findings may not be extrapolated to all patients who have coronary heart disease, because only patients who underwent successful elective percutaneous interventions were included. Therefore, medically and surgically treated patients and those who had unsuccessful procedures were not represented in this study population. Further, the effect of fluvastatin in patients who had severe renal impairment was not assessed in the present study, and more detailed investigations of the nature of renal impairment (e.g., diagnosis of underlying renal pathology or assessment of microalbuminuria or proteinuria) and measurements of biochemical proatherogenic markers were not available. These limitations do not alter the overall conclusion that fluvastatin therapy had a clinically relevant effect in patients who had mild renal impairment.
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